anti-CD3/anti-nectin-4 bispecific T-cell engager CAB platform (BioAtla)

N/A

Report date: 2026/03/19 16:58:21

Base Information

Drug Nameanti-CD3/anti-nectin-4 bispecific T-cell engager CAB platform (BioAtla)
Drug Alias NameCAB nectin-4 x CAB CD3 bispecific antibody (BioAtla)CAB nectin-4 x CAB CD3 bispecific antibody (BioAtla)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsNectin-4 modulators
TargetsNectin-4T cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsPancreatic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBioAtla Inc
China Registration ClassN/A

Develop Information

Active CompaniesBioAtla Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsPancreatic Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A